Company intelligence / Profile preview
SynAct Pharma AB
Lund, Swedensynactpharma.com ↗
- Ownership
- Private
- Employees
- ~6
- Development stage
- Other
01
Overview
SynAct Pharma is currently conducting Phase 2 clinical trials for its lead drug candidate resomelagon (AP1189) in rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. The company recently announced the initiation of a Phase II study with resomelagon for the treatment of patients with dengue in April 2025. They also received a Notice of Allowance for a US Patent covering resomelagon combination therapy.
- Therapeutic areas
- ImmunologyInfectious DiseasesNephrology
- Modalities
- Melanocortin agonistsoral and injectable selective melanocortin agonists
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on SynAct Pharma AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SynAct Pharma AB.